Patent
Methods of diagnosing and predicting renal disease
| العنوان: | Methods of diagnosing and predicting renal disease |
|---|---|
| Patent Number: | 9,791,452 |
| تاريخ النشر: | October 17, 2017 |
| Appl. No: | 13/130711 |
| Application Filed: | December 09, 2009 |
| مستخلص: | This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6. |
| Inventors: | Niewczas, Monika A. (Boston, MA, US); Krolewski, Andrzej S. (Needham, MA, US) |
| Assignees: | Joslin Diabetes Center, Inc. (Boston, MA, US) |
| Claim: | 1. A method of determining whether a human subject has an increased risk of developing chronic kidney disease (CKD), or end stage renal disease (ESRD), or both, the method comprising: obtaining a sample from a human subject who has proteinuria; detecting the presence of and measuring the level of soluble TNF receptor type 1 (sTNFR1) in the subject sample with an anti-sTNFR1 antibody and detecting binding and measuring the level of binding between sTNFR1 and the antibody; comparing the subject levels of sTNFR1 with reference levels of sTNFR1; and determining whether the subject has an increased risk of developing CKD or ESRD, or both, based on the comparison of the subject levels with the reference levels, wherein the presence of sTNFR1 in the subject sample at levels that are significantly higher than the reference levels indicates that the subject has an increased risk of developing CKD, ESRD or both, administering a therapy to subjects identified as having an increased risk of developing CKD or ESRD and monitoring said identified subjects for a reduction in the level of sTNFR1. |
| Claim: | 2. The method of claim 1 , wherein the subject has Type 1 or Type 2 diabetes. |
| Claim: | 3. The method of claim 1 , wherein the sample comprises serum from the subject. |
| Patent References Cited: | 2010/0173936 July 2010 Khan et al. |
| Other References: | Liu et al in “Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury” (Crit Care Med 2007 vol. 35, No. 12, pp. 2755-2761). cited by examiner Keller et al (BMC Nephrology 2008, vol. 9: pp. 1-9). cited by examiner Tonelli et al in “Biomarkers of inflammation and progression of chronic kidney disease” (Kidney International, vol. 68 (2005), pp. 237-245). cited by examiner Knight, Eric L., et al., “Kidney Dysfunction, Inflammation, and Coronary Events: A Prospective Study”, J. Am. Soc. Nephrol., 2004, vol. 15, pp. 1897-1903. cited by applicant Lin et al., The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus, Kidney International, 2006, vol. 69, pp. 336-342. cited by applicant Ng, D.P.K., et al., “Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-x system”, Diabetologia, Oct. 2008, vol. 51, pp. 2318-2324. cited by applicant Rosolowsky, et al., “Between hyperfiltration and impairment: Demystifying early renal functional changes in diabetic nephropathy” Diabetes Research and Clinical Practice, Published on-line Oct. 11, 2008, vol. 82s, pp. s46-s53. cited by applicant Niewczas, et al., “Serum Concentrations of Markers of TNFx and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes” Clinical Journal Am Soc Nephrol, 2009, vol. 4, pp. 62-70 (XP-002683004). cited by applicant |
| Primary Examiner: | Hibbert, Catherine S |
| Attorney, Agent or Firm: | Pierce Atwood LLP Farrell, Kevin M. Wilson, David J. |
| رقم الانضمام: | edspgr.09791452 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |